| Qin Li,Xianrong Li,Libo Feng,Xiaolong Chen,Dong Xia,Linxia Xu. Preliminary security investigation and shorttime follow-up of intraoperative intraperitoneal chemotherapy with lobaplatin for advanced colorectal cancer. Oncol Transl Med, 2023, 9: 93-98. |
| Preliminary security investigation and shorttime follow-up of intraoperative intraperitoneal chemotherapy with lobaplatin for advanced colorectal cancer |
| Received:October 22, 2022 Revised:April 29, 2023 |
| View Full Text View/Add Comment Download reader |
| KeyWord:intraoperative intraperitoneal chemotherapy; lobaplatin; colorectal cancer |
| Author Name | Affiliation | E-mail | | Qin Li | Southwest Medical University Affiliated Hospital | 253303821@qq.com | | Xianrong Li | Southwest Medical University Affiliated Hospital | | | Libo Feng | Southwest Medical University Affiliated Hospital | | | Xiaolong Chen | Southwest Medical University Affiliated Hospital | | | Dong Xia | Southwest Medical University Affiliated Hospital | | | Linxia Xu | Southwest Medical University Affiliated Hospital | 14369372@qq.com |
|
| Hits: 1315 |
| Download times: 1543 |
| Abstract: |
| Objective The aim of this study was to conduct a security assessment of intraoperative intraperitoneal
chemotherapy using lobaplatin for advanced colorectal cancer.
Methods From February 2015 to February 2016, 143 patients with colorectal cancer who underwent
surgery in our department were selected prospectively. All patients were randomly screened and enrolled
into the intraperitoneal chemotherapy (IPC) (74 cases) and control (69 cases) groups, depending on the
distribution of cases in the random table. In the trial group, patients were administered 40 mg lobaplatin
by intraperitoneal implantation intraoperatively, together with intravenous chemotherapy post-operatively
using a typical FOLFOX strategy with oxaliplatin, fluorouracil, and leucovorin. In the control group, only
FOLFOX was administered. Bowel function recovery time, adverse reactions and complications, and preand
post-chemotherapy laboratory examinations were compared. In addition, a 5-year-long follow-up was
performed.
Results Recovery times of bowel function were 73.5 ± 9.7 h and 74.8 ± 10.3 h respectively, and the
difference was not significant (P > 0.05). Wound fat liquefaction was observed in five cases in both groups
(6.8% vs. 7.2%, P > 0.05). The outcomes of nausea and vomiting (57 cases, 77.0% vs. 50 cases, 72.5%),
constipation (43 cases, 58.1% vs. 36 cases, 52.2%), and diarrhea (5 cases, 6.8% vs. 5 cases, 7.2%) were not
statistically significant (all P > 0.05). Indices of white blood cell count, blood platelet count, and hepatorenal
function were not significantly different (all P>0.05) neither post-operatively nor post-chemotherapy. The
5-year survival rate was not significantly different between the groups (58.1% vs. 56.5%, P > 0.05).
Conclusion Intraoperative chemotherapy with lobaplatin for advanced colorectal cancer is safe and
tolerable. |
| Close |
|
|
|